Drug Type Small molecule drug |
Synonyms [(S-S)-[11C]methylreboxetine, (S-S)-[11C]MENER, [11C]-MRB |
Target |
Action modulators |
Mechanism SLC6A2 modulators(Norepinephrine transporter modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H21NO3 |
InChIKeyMZGJHBJKODTIQM-RIVWMEAKSA-N |
CAS Registry634591-18-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | United States | 10 Oct 2017 |
Not Applicable | NE transporters (NET) | 31 | (All HC) | aszjgkutyi(mbizvkeksx) = htgkbsllkv kpqyjwblkq (iqjjiijomx ) | - | 07 Dec 2020 | |
(Male HC) | aszjgkutyi(mbizvkeksx) = bviencdity kpqyjwblkq (iqjjiijomx ) | ||||||
Not Applicable | - | (Male) | yfmbrxilux(ppswgvvlsw) = jyakvbugds odidvlnrbl (qnzphivmvd ) View more | - | 15 May 2020 | ||
(Female) | yfmbrxilux(ppswgvvlsw) = lyumkjncux odidvlnrbl (qnzphivmvd ) View more |